PubMed Health⌕ Search

Biomedical subjects

G Frithz

Publications and source records attributed to G Frithz.

At least 37 records · Page 2Linked to original sources
PubMed1987

Efficacy and safety of bisoprolol and atenolol in patients with mild to moderate hypertension: a double-blind, parallel group international multicentre study.

Three hundred and fifteen patients were randomly allocated to treatment for six months with bisoprolol 5 or 10 mg day-1 or atenolol, 50 mg day-1, in a double-blind, double-dummy parallel group, international multicentre study. Two hundred and ninety-two (175 men and 117 women) were eligible for statistical follow-up. Their mean age was 52.6 years (range 28-70). All patients had a supine diastolic blood pressure of 95-120 mmHg on two occasions during the four weeks of placebo treatment. Twenty-four patients ended the study prematurely and a further 19 had their regimes changed because of an insufficient effect. The reasons for drop-out were similar in the three treatment groups. Thus, 249 patients continued to receive the treatment they were allocated to, with 80, 83 and 86 patients in the three respective groups. The sex and age distributions and the number of previously treated hypertensives were similar in the three groups. At the end of placebo treatment the supine blood pressures in the three groups (bisoprolol 5 or 10 mg day-1 or atenolol 50 mg day-1, respectively) were 163.9/102.5, 157.4/101.8 and 160.0/102.2 mmHg, respectively. The systolic blood pressure was higher (P less than 0.05) in the group receiving bisoprolol 5 mg day-1 than in the 10 mg day-1 group. After 26 weeks of treatment the supine blood pressures in the three groups were 150.6/90.8, 142.0/89.1 and 148.6/91.7 mmHg, respectively. The largest estimated difference in blood pressure reduction was 4.6/2.3 mmHg between the group receiving bisoprolol 10 mg day-1 and the group receiving atenolol 50 mg day-1. A reduction in mean blood pressure of greater than or equal to 10 mmHg was noted in 66% of the patients in the bisoprolol group (10 mg day-1), in the other groups 66 and 59%, n.s. Bisoprolol is effective, well-tolerated and safe in the treatment of hypertension. A daily dose of 5 mg seems recommendable for the majority of hypertensive patients and seems equipotent with 50 mg day-1 of atenolol in the present study.

Adult↗
PubMed1987

Treatment of severe hypertension with peroral labetalol.

22 patients with untreated, essential hypertension (diastolic blood-pressure greater than or equal to 140 mmHg) and in most cases also showing neurological symptoms were given a single oral dose of 400 mg labetalol. All patients displayed a gradual decrease of the blood-pressure down to a diastolic pressure about 110 mmHg with relief of the symptoms. There were no signs of neurological deficit due to the reduction of blood-pressure.

Administration, Oral↗
PubMed1986

Aberrant protein pattern in red cell membranes of a patient with mild hemolytic anemia.

A 17-year-old patient with mild hemolytic anemia known since early childhood displayed an aberrant protein pattern of his red cell membranes when analyzed in SDS-polyacrylamide gel electrophoresis (SDS-PAGE). A double protein band in the low molecular weight region (molecular weight of about 33,000) was distinctly reduced or missing in the membranes that were investigated concomitantly with those of controls on two occasions at an interval of 6 months'. The phosphorylation pattern of membrane phosphoproteins, on the other hand, did not seem to differ from that of controls. It is suggested that a causal relationship existed between the observed membrane abnormality and the mild hemolytic anemia.

Adolescent↗
PubMed1986

Antihypertensive effects of bisoprolol during once daily administration in patients with essential hypertension. A dose-ranging study with parallel groups.

Bisoprolol is a new beta 1-selective beta-blocking agent with a plasma half-time of 10-12 h and without partial agonist properties. Forty-eight patients with essential hypertension were randomly treated with 5, 10, or 20 mg bisoprolol given once daily for 8 weeks. All measurements were made 24 hours after the last dose. Bisoprolol had antihypertensive and beta-blocking properties both at rest and during exercise. The 20 mg dosage regimen was more effective than that of 5 mg and 10 mg. The drug was well tolerated and all the 48 patients completed the trial.

Adrenergic beta-Antagonists↗
PubMed1986

Dose-effect relationship and long-term effects of bisoprolol in mild to moderate hypertension.

In an initial double-blind randomized study with three parallel groups, 48 patients, mean age 49.6 years (32-65 years), with hypertension WHO I-II, were given bisoprolol in doses of 5, 10, and 20 mg. Bisoprolol is a new beta 1-selective beta-blocking agent with a plasma half-life of 10-12 h and without intrinsic sympathomimetic activity (ISA). After the initial 8 weeks, systolic (SBP) and diastolic blood pressure (DBP) and heart rate (HR) measured at rest and during exercise 24 h after last drug intake showed a significant decrease for all three parameters in all three treatment groups. There were no differences in efficacy between the 5 and 10 mg doses of bisoprolol, whereas 20 mg was significantly more effective than both 5 mg (p less than 0.01) and 10 mg (p less than 0.05). After 10 months of treatment with dose adjustments up or down, the reduction of SBP, DBP, and HR at rest and during exercise remained unchanged. One patient had an acute myocardial infarction (AMI) and died during the study; another patient had a car accident in which he got asphyxial cerebral lesions and could not complete the study. Twelve patients spontaneously expressed side effects of the kind normally seen in treatment with beta-blocking agents. Three of them complained of cold hands and feet, and one of them was unable to complete the study. The rest of the adverse effects were mild, and 45 patients completed the long-term study. Laboratory safety tests were normal, and there were no significant changes in the lipoprotein patterns (cholesterol, HDL cholesterol, and triglycerides).(ABSTRACT TRUNCATED AT 250 WORDS)

Adrenergic beta-Antagonists↗
PubMed1986

Long-term effects of bisoprolol on blood pressure, serum lipids, and HDL-cholesterol in patients with essential hypertension.

The objective of the study was to evaluate the effect of continuous therapy with bisoprolol on blood pressure, serum lipids, and HDL-cholesterol over a period of 10 months following an initial 3-month titration and short-term treatment period. The results of the short-term study have been presented in a separate report. Forty-two patients entered into this long-term study, and 41 of them completed the 10-month treatment period. The mean supine blood pressure was 134/85 mm Hg at the end of the short-term study and was maintained at 137/85 mm Hg after 10 months on bisoprolol. At the end of the study, all patients but one had a supine diastolic blood pressure of less than or equal to 90 mm Hg with a dose of 2.5-40 mg bisoprolol. Three of the patients required concomitant use of hydrochlorothiazide to keep this pressure level. A small but statistically significant increase in serum triglycerides was observed from the start of the titration period to the end of the long-term study. Within each study, the changes were not significant. No significant changes were observed for total cholesterol, or for low density lipoprotein (LDL)- or high density lipoprotein (HDL)-cholesterol. The side effects were rare and the usual for beta-blockers.

Adrenergic beta-Antagonists↗
PubMed1985

Serum sialyltransferase and fucosyltransferase activities in patients with multiple myeloma.

A significant elevation of serum sialyltransferase and fucosyltransferase mean activities was observed in 19 untreated patients with multiple myeloma. However, sialyltransferase mean activity was significantly lower in 13 other patients treated for 1-30 months with alkylating drugs and prednisolone. Such a definite decrease in serum enzyme activity on treatment was not recorded for fucosyltransferase. Instead, this activity was significantly increased in treated patients as compared to controls. The presenting clinical features of the 32 patients with multiple myeloma were the basis for a clinical staging system with regard to myeloma cell burden according to established criteria. In untreated patients (as opposed to treated ones), a significantly higher serum sialyltransferase (but not fucosyltransferase) activity was obtained among those 11 belonging to stage III than among the other eight with stages I and II, suggesting a link between tumour burden and enzyme activity. This assumption was further strengthened in those six patients followed lengthwise with regard to serum sialyltransferase activity. Concomitantly with objective evidence of change in tumour burden they showed corresponding alterations in sialyltransferase activity. The determination of sialyltransferase and fucosyltransferase activity in serum may be an additional contribution to refine initial assessment and follow-up of individual patients with multiple myeloma.

Aged↗
PubMed1984

A long-term follow-up of patients with essential hypertension treated with captopril.

Seventy-four patients from four short-term studies of captopril in mild-moderate essential hypertension continued in a cooperative long-term efficacy and tolerance program. The duration of observation is 2- greater than 4 years, the total treatment time being 2434 months. No development of resistance to therapy was observed. The total daily dose of captopril has been gradually decreased and in 20 patients changed from t.i.d. to b.i.d. regime. The drug has been well tolerated and only few and mild side-effects have been observed after the initial titration period. The drop-outs (n = 19) were mostly due to non-medical causes (n = 14). Except for one case of proteinuria, no laboratory abnormalities were detected and there were no signs of long-term toxicity.

Adult↗
PubMed1983

Urinary adenylate kinase isoenzyme pattern in patients with myocardial infarction.

Adenylate kinase was purified in pooled urinary samples from patients with uncomplicated myocardial infarction. The purification procedure included ammonium sulfate precipitation and column chromatographic steps. It was necessary to stabilize the enzyme during purification with 2-mercaptoethanol and AMP. Polyacrylamidgelelectrophoresis in sodium dodecanyl sulfate revealed the release of 4 different isoenzymes of AK into urine from patients with myocardial infarction. The molecular weights of these isoenzymes were estimated to be 21,000; 24,000; 33,000 and 36,000, respectively.

Adenylate Kinase↗
PubMed1982

Once-a-day treatment of hypertension with pindolol.

Administration of a once-daily dosage of pindolol seems to be a simple and effective way to treat mild to moderate hypertension and one that produces relatively few side effects. In most cases, gradual titration of the drug seems unnecessary and the optimum dose can be given initially without increasing the risk of side effects. Thus, a simpler regimen can be instituted which may encourage patient compliance--a factor of great importance in view of the long duration of the therapy.

Adult↗
PubMed1982

Peripheral vasodilatation in the treatment of hypertension. Prazosin compared with hydralazine in patients not responding to beta-receptor blockade.

Prazosin was compared with hydralazine in 39 patients (mean age 49 years), who were already on beta-blockade for arterial hypertension. They all had a resting DBP greater than 100 mm Hg on propranolol 80 mg b i d. They were randomly allocated to prazosin or hydralazine treatment. Blood pressure was measured after 4, 8 and 12 weeks. We noted a significant fall in blood pressure in both groups, in most cases to normotensive levels. Side-effects and other variables of interest are discussed. Together with beta blockade, i e propranolol, both prazosin and hydralazine give good blood-pressure control and no important differences could be found.

Adult↗
PubMed1982

Effect of cardiac glycosides on the release of adenylate kinase into cerebrospinal fluid of patients with cerebral arteriosclerosis.

48 patients with cerebral arteriosclerosis were found to have a manifest release of adenylate kinase (AK) into cerebrospinal fluid (CSF). This release was most probably due to an increased leak in the brain cells subsequent to a lowered adenylate charge potential followed by a diminished electrochemical potential in these cells suffering from disturbed oxygen supply. A further increase of AK release into CSF was noted for the 22 patients receiving cardiac glycosides compared to the 26 patients not treated with these drugs. The mean AK value of the former group was 0.119 +/- 0.028 U/l compared to that of the latter group, being 0.089 +/- 0.025 U/l, and this difference was significant (p less than 0.001). The effect of cardiac glycosides is most probably explained by an additional lowering of the membrane electrochemical potential in brain cells of these patients due to the direct action of cardiac glycosides on the Na+- and K+-dependent ATPase system in these cells, resulting in an increased leak in the plasma membrane.

Adenylate Kinase↗
PubMed1981

Comparison of captopril (SQ 14225) with hydrochlorothiazide in the treatment of essential hypertension.

Captopril, a newly developed, orally active inhibitor of the angiotensin-converting enzyme, and hydrochlorothiazide were given alone or in combination to 39 patients with mild or moderate essential hypertension. After a placebo period the patients were randomly allocated in the proportion 3:2 to treatment with captopril (n = 23) or hydrochlorothiazide (n = 16) for dose titration over 4 weeks. The alternative test drug was added thereafter during an 8-week maintenance period if the supine diastolic blood pressure was more than 90 mmHg. The average supine BP reduction in the captopril group was 29/21 mmHg and in the hydrochlorothiazide group 18/15 mmHg. Only one patient who started on captopril had to have hydrochlorothiazide added. Four of those who started on hydrochlorothiazide had to have captopril added. The antihypertensive effects of captopril and hydrochlorothiazide appear to be additive. Among the side effects due to captopril, there were two patients with taste disturbances and another two with rashes.

Adult↗
PubMed1979

Increased red cell content of Zn2+ in essential hypertension.

The zinc content in plasma as well as in erythrocytes was studied in 61 patients with untreated essential hypertension. They displayed an intraerythrocytic mean value of Zn2+ of 128.2 micromoles/l intracellular water, which is significantly higher than the corresponding mean of 101.5 micromoles/l from 42 normal persons. In plasma, on the other hand, the mean zinc value of the hypertensive persons was 15.2 micromoles/l plasma, i.e. well within the normal range of plasma Zn2+. Possible mechanisms underlying the elevated red cell zinc level in hypertension are discussed.

Adult↗